A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Inclusion Criteria:

* Age≥18 years, ≤75 years, male or female
* Advanced renal cell carcinoma is diagnosed histologically or pathologically
* Treatment naive at diagnosed
* At least one measurable tumor lesion (Response Evaluation Criteria In Solid Tumors)
* Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1
* The expected life span is ≥12 weeks
* No contraindications for targeted therapy, with enough liver function and renal function and normal ECG recording Peripheral hemogram: neutrophil≥1.5×109/L, Plt≥100×109/L, Hgb≥90g/L Renal function: serum creatinine≤1.5 folds the upper limit of normal (ULN) For patients with non-metastatic liver dysfunction:alanine aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN
* The patients participate voluntarily and have signed the informed consent form

Exclusion Criteria:

* Patients who have received any systemic therapy including targeted therapy,immunotherapy,chemotherapy etc at diagnosed.
* Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures
* Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds
* Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension
* Patients with a history of HIV infection or active phase of chronic hepatitis B/C
* negative imaging examination result 4 weeks prior to enrollment)
* Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs)
* A history of allogeneic organ transplantation